Adrienne K Barry, MD
Dermatology · San Rafael
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 8
- 1 carrier
- Office
- 1
- Since medical school
- 9 years
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 2017
Offices
1 location · Joseph H Greenberg Ltd A Medical Corp · 4 clinicians in this group
Plans that list them
8 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Barry’s office at (415) 472-3903 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A159987 · Current
Licensed to practise in California · since 2018 · expires 2028-12-31 · University of Illinois College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Illinois 125069958Temporary Medical Permit · since 2017 · expires 2018-06-30Specialty on the licence: Internal MedicineExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Dermatology - Dermatology
Original Medicare doctor bills
$60,726
Medicare paid this office $60,726 for 258 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Destruction of skin growth, 1-14 growths | 95 | $11,313 | $101 |
| Short return visit (20+ min) | 112 | $10,329 | $73 |
| New patient visit (30+ min) | 101 | $6,556 | $65 |
| Destruction of precancer skin growth, 1 growth | 122 | $6,479 | $46 |
| New patient visit (45+ min) | 53 | $6,063 | $114 |
See all 10 services
| Destruction of skin growth, 1-14 growths | 95 | $11,313 | $101 |
| Short return visit (20+ min) | 112 | $10,329 | $73 |
| New patient visit (30+ min) | 101 | $6,556 | $65 |
| Destruction of precancer skin growth, 1 growth | 122 | $6,479 | $46 |
| New patient visit (45+ min) | 53 | $6,063 | $114 |
| Return visit (30+ min) | 43 | $5,603 | $104 |
| Destruction of precancer skin growth, 2-14 growths | 97 | $3,397 | $7 |
| Biopsy of related skin growth, first growth | 38 | $3,343 | $80 |
| Punch biopsy, first skin growth | 13 | $1,640 | $126 |
| Short return visit | 11 | $439 | $40 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 553 | More than 88% of doctors who do this |
| Skin biopsy | 118 | More than 78% of doctors who do this |
Procedures year by year
| Procedure | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 247 | 433 | 428 | 507 |
| Destruction of precancer skin growth, 1 growth | 58 | 127 | 125 | 142 |
| Destruction of skin growth, 1-14 growths | 13 | – | 65 | 112 |
| Biopsy of related skin growth, first growth | 24 | 76 | 37 | 42 |
| Punch biopsy, first skin growth | 14 | 30 | 18 | 13 |
| Biopsy of related skin growth, each additional growth | – | 20 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
258 Original Medicare patients in 2024. Average age 77 · Under 65 0% · 85 and older 14% · Women 58% · Health risk score 0.97. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 59% · Coronary heart disease 20% · Atrial fibrillation 18% · Cancer 17% · Chronic kidney disease 16% · Diabetes 14% · Depression 14% · Heart failure 9% · COPD 8% · Dementia 5% · Stroke 4%.
The office billed $150,491, Medicare allowed $93,904 and paid $60,726; for 1,245 services of 32 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 258 | 1,245 | 77 | 0.97 | $150,491 | $60,726 |
| 2023 | 250 | 1,020 | 76 | 0.84 | $117,662 | $55,970 |
| 2022 | 280 | 1,304 | 78 | 0.87 | $184,495 | $67,918 |
| 2021 | 121 | 588 | 76 | 0.86 | $73,370 | $29,470 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| New patient visit (30+ min) | 162 | $15,905 | $98 |
| Short return visit (20+ min) | 76 | $7,336 | $83 |
| Destruction of skin growth, 1-14 growths | 59 | $7,248 | $112 |
| Destruction of precancer skin growth, 1 growth | 112 | $6,194 | $50 |
| Biopsy of related skin growth, first growth | 36 | $3,368 | $91 |
| New patient visit (45+ min) | 20 | $3,091 | $155 |
| Destruction of precancer skin growth, 2-14 growths | 91 | $2,983 | $7 |
| Punch biopsy, first skin growth | 17 | $2,324 | $129 |
| Return visit (30+ min) | 15 | $1,920 | $120 |
2022: 12 services
| Short return visit (20+ min) | 196 | $19,904 | $71 |
| Biopsy of related skin growth, first growth | 68 | $7,234 | $95 |
| Destruction of precancer skin growth, 1 growth | 105 | $5,923 | $47 |
| New patient visit (30+ min) | 71 | $5,600 | $79 |
| Pathology examination of tissue using a microscope, intermediate complexity | 39 | $4,002 | $69 |
| Punch biopsy, first skin growth | 29 | $3,698 | $123 |
| Short return visit | 55 | $3,499 | $49 |
| Destruction of precancer skin growth, 2-14 growths | 84 | $2,927 | $7 |
| Return visit (30+ min) | 20 | $2,656 | $115 |
| Biopsy of related skin growth, each additional growth | 16 | $1,032 | $52 |
| Injection into skin growth, 1-7 growths | 11 | $761 | $51 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $16 | None |
2021: 9 services
| Short return visit (20+ min) | 73 | $7,386 | $86 |
| Destruction of precancer skin growth, 1 growth | 54 | $3,050 | $53 |
| New patient visit (30+ min) | 29 | $2,969 | $102 |
| Biopsy of related skin growth, first growth | 24 | $2,360 | $98 |
| Pathology examination of tissue using a microscope, intermediate complexity | 26 | $2,249 | $70 |
| Punch biopsy, first skin growth | 14 | $1,872 | $134 |
| Short return visit | 25 | $1,793 | $53 |
| Destruction of precancer skin growth, 2-14 growths | 45 | $1,672 | $7 |
| Destruction of skin growth, 1-14 growths | 12 | $1,523 | $117 |
Medicaid work
$6,713 in 2020
Medicaid paid $6,713 for 54 billed services this clinician did in 2020, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 22 | $6,713 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 15 | $0 |
| Service | 17 | $0 |
| 2020 | 54 | 3 | 21 | $6,713 |
| 2019 | 111 | 3 | 28 | $8,629 |
| 2018 | 16 | 1 | 16 | $0 |
See the largest Medicaid services in earlier years
2019
| Clinic visit/encounter, all-inclusive | 28 | $8,629 |
| Short return visit (20+ min) | 56 | $0 |
| Service | 27 | $0 |
2018
| Short return visit (20+ min) | 16 | $0 |
Drugs they prescribed that Part D paid
$93,233
Pharmacies billed $93,233 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 712) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
657 generic and 55 brand-name prescriptions · $93,233 in drug cost · 37 antibiotic prescriptions to 24 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 138 | $6,036 | $44 |
| Tacrolimus | 42 | $5,265 | $125 |
| Calcipotriene | 23 | $2,608 | $113 |
| Fluorouracil | 33 | $1,738 | $53 |
| Ketoconazole | 96 | $1,401 | $15 |
See all 16 drugs
| Clobetasol Propionate | 138 | $6,036 | $44 |
| Tacrolimus | 42 | $5,265 | $125 |
| Calcipotriene | 23 | $2,608 | $113 |
| Fluorouracil | 33 | $1,738 | $53 |
| Ketoconazole | 96 | $1,401 | $15 |
| Doxycycline Monohydrate | 30 | $1,103 | $37 |
| Metronidazole | 20 | $1,012 | $51 |
| Fluocinonide | 18 | $556 | $31 |
| Hydrocortisone | 70 | $462 | $7 |
| Triamcinolone Acetonide | 24 | $393 | $16 |
| Doxycycline Hyclate | 12 | $300 | $25 |
| Nystatin | 17 | $278 | $16 |
| Mupirocin | 33 | $255 | $8 |
| Ciclopirox | 12 | $218 | $18 |
| Minoxidil | 20 | $181 | $9 |
| Terbinafine | 14 | $128 | $9 |
Year by year
| 2024 | 712 | 311 | 0% (0) | 8% | $93,233 |
| 2023 | 627 | 266 | 0% (0) | 7% | $119,845 |
| 2022 | 379 | 128 | None | 3% | $59,740 |
| 2021 | 166 | 81 | 0% (0) | 7% | $8,869 |
| 2019 | 19 | 12 | 0% (0) | None | $1,761 |
| 2018 | 25 | None | 0% (0) | None | $3,237 |
| 2017 | 17 | None | None | None | $1,145 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Otezla | 14 | $66,830 | $4,774 |
| Tacrolimus | 36 | $6,485 | $180 |
| Calcipotriene | 49 | $4,836 | $99 |
| Clobetasol Propionate | 85 | $3,405 | $40 |
| Fluocinonide | 42 | $2,999 | $71 |
| Fluorouracil | 60 | $2,577 | $43 |
| Ketoconazole | 53 | $1,029 | $19 |
| Metronidazole | 14 | $598 | $43 |
| Doxycycline Monohydrate | 14 | $561 | $40 |
| Nystatin | 20 | $437 | $22 |
| Hydrocortisone | 49 | $431 | $9 |
| Mupirocin | 37 | $410 | $11 |
| Triamcinolone Acetonide | 25 | $362 | $14 |
| Clindamycin Phosphate | 13 | $303 | $23 |
| Ciclopirox | 14 | $269 | $19 |
| Terbinafine | 12 | $229 | $19 |
| Minoxidil | 15 | $114 | $8 |
2022: 11 drugs
| Tacrolimus | 16 | $3,196 | $200 |
| Clobetasol Propionate | 37 | $2,460 | $66 |
| Fluocinonide | 33 | $1,732 | $52 |
| Doxycycline Monohydrate | 17 | $1,689 | $99 |
| Fluorouracil | 13 | $1,121 | $86 |
| Metronidazole | 12 | $1,028 | $86 |
| Betamethasone Dipropionate | 17 | $894 | $53 |
| Ketoconazole | 48 | $645 | $13 |
| Triamcinolone Acetonide | 24 | $375 | $16 |
| Mupirocin | 30 | $216 | $7 |
| Hydrocortisone | 29 | $164 | $6 |
2021: 4 drugs
| Clobetasol Propionate | 17 | $1,477 | $87 |
| Ketoconazole | 18 | $398 | $22 |
| Mupirocin | 12 | $101 | $8 |
| Hydrocortisone | 13 | $65 | $5 |
Money from drug and device companies
$167 in 2025
| 2025 | 5 | 7 | None | $167 |
| 2024 | 9 | 36 | None | $899 |
| 2023 | 8 | 17 | None | $426 |
| 2022 | 12 | 75 | None | $2,746 |
| 2021 | 6 | 25 | None | $858 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ucb | Bimzelx | $53 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $46 | 2 payments
|
| Verrica Pharmaceuticals | Ycanth | $23 | 1 payment
|
| Amgen | Otezla | $23 | 1 payment
|
| Abbvie | Botox | $22 | 1 payment
|
See all 7 published payments
| Ucb | Meals · 2025-11-18 | Bimzelx | $26 |
| Novartis Pharmaceuticals | Meals · 2025-11-03 | Rhapsido | $20 |
| Novartis Pharmaceuticals | Meals · 2025-09-17 | Cosentyx | $26 |
| Verrica Pharmaceuticals | Meals · 2025-05-31 | Ycanth | $23 |
| Ucb | Meals · 2025-05-20 | Bimzelx | $27 |
| Amgen | Meals · 2025-05-05 | Otezla | $23 |
| Abbvie | Meals · 2025-01-14 | Botox | $22 |
See earlier years (2024, 2023, 2022, 2021)
2024: $899
| Abbvie | Rinvoq | $217 | 14 payments
|
| Janssen Biotech | Tremfya | $186 | 5 payments
|
| Lilly USA | Taltz | $121 | 4 payments
|
| Dermavant Sciences | Vtama | $96 | 2 payments
|
| Arcutis Biotherapeutics | Zoryve | $76 | 3 payments
|
| Incyte | Opzelura | $66 | 3 payments
|
| Genzyme | Dupixent | $59 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $50 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $28 | 1 payment
|
2023: $426
| AbbVie | Skyrizi | $203 | 8 payments
|
| Pfizer | Cibinqo | $44 | 2 payments
|
| Lilly USA | Taltz | $36 | 2 payments
|
| Amgen | Otezla | $34 | 1 payment
|
| Janssen Biotech | Tremfya | $32 | 1 payment
|
| LEO Pharma | Adbry | $29 | 1 payment
|
| Incyte | Opzelura | $29 | 1 payment
|
| Almirall | Klisyri | $18 | 1 payment
|
2022: $2,746
| Abbvie | Skyrizi | $860 | 19 payments
|
| Allergan | Botox | $403 | 27 payments
|
| Pfizer | Cibinqo | $323 | 4 payments
|
| Merz North America | None | $221 | 4 payments
|
| LEO Pharma | Adbry | $214 | 4 payments
|
| Genzyme | Dupixent | $171 | 3 payments
|
| Janssen Biotech | Remicade | $154 | 6 payments
|
| Regeneron Healthcare Solutions | Libtayo | $147 | 2 payments
|
| Galderma Laboratories L.P. | Twyneo | $141 | 2 payments
|
| Incyte | Opzelura | $46 | 2 payments
|
| Amgen | Otezla | $35 | 1 payment
|
| Lilly USA | Taltz | $31 | 1 payment
|
2021: $858
| Allergan | Botox | $278 | 10 payments
|
| AbbVie | Skyrizi | $243 | 9 payments
|
| Genzyme | Dupixent | $150 | 3 payments
|
| Janssen Scientific Affairs | Tremfya | $122 | 1 payment
|
| Janssen Biotech | Remicade | $37 | 1 payment
|
| Lilly USA | Taltz | $28 | 1 payment
|
Professional record
- NPI
- 1316475270
- Licence
- CA A159987, IL 125069958California A159987: Current · expires 2028-12-31Illinois 125069958: Expired
- Trained
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 2017 · 9 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Internal medicine (207R00000X)
- Mailing address
- 450 Sutter St Rm 1823, San Francisco, CA, 94108
- NPI first listed
- 2017-05-23
- NPI last updated
- 2025-03-07
- NPI record certified
- 2025-03-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 750 Las Gallinas Ave Ste 205, San Rafael, CA, 94903
This office lists an electronic records connection.